San Diego-based mostly Viking Therapeutics marked itself as a significant competitor in the weight loss drug marketplace in February immediately after revealing promising facts from a mid-stage demo of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when supplied being a weekly injection and in March